Skip to main content
    T

    TherapeuticsMD Inc (TXMD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.81
    -0.06 (-3.21%)

    Market Cap: $21.64M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    TherapeuticsMD Inc (TXMD) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    TherapeuticsMD (TXMD) trades at 5.6x sales and 0.8x book value. Its P/S of 5.6x is below its 10-year median of 11.2x. Its forward P/E is 2.3x.

    Current Multiples

    Its enterprise value is 5.7x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E2.3x
    Price to sales5.6x
    Price to book0.8x
    EV/EBITDA5.7x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S5.6xN/A11.2x
    Medians of month-end values through Oct 2026: 103 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.3x in 2022 to 74.2x in 2017.

    Year endPriceP/EP/SP/B
    2025$1.6322.7x6.2x0.7x
    2024$0.86N/A5.6x0.4x
    2023$2.25N/A18.1x0.9x
    2022$5.590.5x1.3x124.9x
    2021$17.78N/A16.2xN/A
    2020$60.50N/A5.2xN/A
    2019$121.00N/A12.1x68.8x
    2018$190.50N/A53.4x9.3x
    2017$302.00N/A74.2x10.1x
    2016$288.50N/A58.4x8.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TXMD

    What is TXMD's forward P/E ratio?

    TherapeuticsMD has a forward P/E ratio of 2.3x.

    Is TXMD stock overvalued?

    GNG's valuation label for TXMD is Undervalued.

    What is TXMD's price to sales ratio?

    TherapeuticsMD has a price to sales ratio of 5.6x.